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It should be noted that whereas both the membrane bound form and
the soluble form of SCF can stimulate the SCF receptor, there are
differences in the duration and perhaps signaling pathways stimulated
by these different forms of the molecule (Toksoz et al, 1992; Miyazawa
and Williams, 1995; Wehrle-Haller and Weston, 1995)
Soluble cutaneous SCF appears to be present at low levels, and we
have only been able to demonstrate it in skin by using a sensitive
immunoperoxidase technique with long incubations (Longley et al,
1993, 1996, 1997a). Our original studies used formalin fixed tissue, in
which there may be extensive cross-linking of proteins. This could
prevent loss of a small soluble molecule such as SCF. Our collaborators
have reproduced our results in another laboratory using frozen sections,
and the same immunoperoxidase detection system (Weiss et al, 1995),
but with a different, commercially available antibody. Professor Henz’s
group used frozen samples with an alkaline phosphatase-anti-alkaline
phosphatase technique, different antibodies, and shorter incubations. I
believe the difference in the detection systems is most important
although it is possible that there also may have been loss of some
soluble SCF from the frozen sections or differences in the antibody
recognition. Despite those differences, Professor Henz’s group did
confirm our result of decreased keratinocyte SCF staining in lesions of
urticaria pigmentosa.
The issue of the presence or absence of soluble SCF and whether
or not keratinocyte associated as SCF remains the same or is decreased
in mastocytosis lesions is not trivial if we are to understand the
pathogenesis of this disease and the potential functions of mast cells in
the skin. We have clearly demonstrated that at least some forms of
urticaria pigmentosa are true neoplasms characterized by activating
cKIT somatic mutations limited to mast cells (Longley et al, 1996).
The c-KIT activating mutations we found in mast cells could not
directly affect melanocytes, and therefore cannot be invoked as an
explanation for increased melanin production seen both clinically and
histopathologically in lesions of cutaneous mastocytosis. What is a
possible explanation for all three observations, the hyperpigmentation,
the altered distribution of SCF, and the presence of activating SCF
mutations? We have hypothesized that neoplastic mast cells, whose
proliferation is driven by mutated mast cell growth factor receptor
(KIT), induce the release of membrane bound keratinocyte SCF
(Longley et al, 1993). The resulting solublized SCF might then stimulate
melanocytes in the lesions to produce melanin, and also stimulate the
mast cells to further proliferation. In support of this theory, we have
recently discovered that the mast cell enzyme chymase, which can be
present in extremely high concentrations in the vicinity of mast cells,
is capable of specifically cleaving SCF, leaving a soluble, bioactive
fragment (Longley et al, 1997b). We currently favor the hypothesis
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To the Editor:
I read with interest the article by Wei et al (1997) regarding the
correlation between DNA repair capacity and metastatic potential of
K-1735 murine melanoma cells; however, the concept of failure of
apoptosis in cancer has not been adequately considered.
The development of cancer is related to the survival of abnormal
cells within preneoplastic lesions by a failure of apoptosis due to the
dysfunction of tumor suppressor genes such as p53 or the existence of
other genes that promote cell survival such as bcl-2. Furthermore,
progression of neoplasia to metastasis may be associated with an
increased rate of mutations and greater resistance to apoptosis. The
percentage of p53 mutations is higher in metastatic melanoma lesions
than in primary tumors (Sparrow et al, 1995) and highly metastatic
B16 melanoma cells exhibit superior survival and resistance to apoptosis
compared with poorly metastatic cells (Glinsky and Glinsky, 1996).
that the neoplastic mast cells in mastocytosis release chymase, which
causes increased conversion of membrane bound keratinocyte SCF to
soluble SCF, which then feeds back to stimulate both mast cell growth
and melanocyte pigment production. This phenomenon would explain
the appearance of soluble SCF and the decrease in keratinocyte
associated SCF. This represents a novel feedback loop, in which a cell
releases a substance which causes secondary release from the surrounding
environment of a growth factor that is necessary for proliferation of
the cell, and has features of both paracrine and autocrine stimulation.
We have therefore named it ‘‘parautocrine’’ stimulation. We believe
that parautocrine stimulation in mastocytosis represents an exaggeration
of a process that is normally seen in inflammatory conditions involving
mast cells in the skin, and could be responsible for such phenomenon
as post-inflammatory hyperpigmentation and the proliferation of mast
cells at sites of chronic inflammation.
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In the host cell reactivation assay used by Wei et al (1997), damaged
plasmid (pCMVcat) encoding chloramphenicol acetyl transferase (CAT)
is transfected into cells. Following incubation, CAT activity is taken
to represent the extent of repair of pCMVcat by the various cell lines
and thus their DNA repair capacity. There is no mention of the
number of cells surviving per well at the end of the incubation.
An alternative interpretation of their results is that repair-proficient
skin fibroblasts, nonmetastatic, and metastatic melanoma cell clones
have similar DNA repair capacity; however, although nonmetastatic
melanoma cells and repair-proficient skin fibroblasts have functioning
p53 pathways, the metastatic cell clones have abnormal apoptotic
pathways. This results in a greater CAT acitivity per extract in the
assay, not due to a greater DNA repair capacity, but to greater survival
of the metastatic melanoma cells from a failure of apoptosis to occur
following transfection of damaged DNA (pCMVcat).
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I thank other researchers at the Centenary Institute for their help in the analysis of this letter.
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Reply:
Dr. Colin Ong pointed out that in a recent article (Wei et al, 1997)
we did not explore an alternative explanation for the correlation of
highly metastatic potential of melanoma cells with increased DNA
repair capacity as measured by a host-cell reactivation (HCR) assay.
(Athas et al, 1991). Dr. Ong provided an interesting interpretation for
such a correlation, i.e., the seemingly enhanced DNA repair capacity
in highly metastatic melanoma cells may be due to an abnormal
apoptosis pathway that delayed cell death, a cellular mechanism that
leads to tumorigenesis resulting from enhanced survival (Glinsk and
Glinsky, 1996). Although this speculation is possible and well worth
discussing, a more pertinent question is whether DNA repair capacity
is an indicator of cellular survival or whether the HCR assay truly
measures cellular DNA repair capacity.
To answer these questions, it is worthwhile elaborating on this
increasingly popular assay. The HCR assay utilizes a nonreplicating
plasmid, pCMVcat, harboring a reporter gene chloramphenicol acetyl
transferase (CAT), which is a bacterial drug-resistant gene that is foreign
to mammalian or human cells (Athas et al, 1991). This feature provides
a highly specific measurement for its expression in human host cells
being transfected. The transfection method utilizes diethylaminoethyl
(DEAE)-dextran, a positively charged polymer nontoxic to cells at the
concentration used for transfection (Fregeau and Bleackley, 1991). Any
measured expression or CAT activity from the plasmid damaged prior
to transfection is a net result from the repair mechanism within the
host cells, because it has been demonstrated that a single, unrepaired
damage, either thymine dimer formed by ultraviolet light (Protic-
Sabljic and Kraemer, 1985) or a bulky DNA adduct formed by
benzo[a]pyrene diol epoxide (Koch et al, 1993), can effectively block
the gene expression.
In the HCR assay, the fact that the cells are not treated by carcinogens
and that pCMVcat is nonreplicating excludes the possibility of its
expression as a function of cell growth after transfection, because the
DEAE-dextran used for transfection is nontoxic to the host cells and
the number of plasmids does not increase as the number of host cells
increases due to cell division. Indeed, transfection-associated cell death
is a constant concern in using quantitative assays requiring transfection.
In our experiments, more than 90% of damaged plasmids used
maintained their supercoiled conformation and the rest were in nicked
form (Athas et al, 1991; Wei et al, 1996). It is demonstrated by others
that in transfection, supercoiled and nicked plasmid DNA and circular
DNA with a small gap did not effectively induce p53-dependent arrest,
whereas linearized or circular plasmid DNA induced by double strand
breaks did (Huang et al, 1996). With a newly developed fluorescence
in situ hybridization (FISH) method, we also demonstrated that with
DEAD-dextran mediated transfection, cells deficient in nucleotide
excision repair exhibited virtually no differences in transfection
efficiency when compared with repair-proficient cells immediately
(1 h) after transfection or before (40 h later) harvesting for gene
expression (Cheng et al, 1996). The similar levels of baseline expression
observed in both repair-deficient and repair-proficient cells is an
indication that transfection does not cause differential cell death rate
associated with inherited DNA repair capacity. Such a DNA repair
measurement independent from cell survival is considered a major
advantage over other DNA repair assays such as unscheduled DNA
synthesis assay (Evan and Norman, 1968), in which cells are directly
damaged and their DNA repair capacity may be compromised and
dependent on cellular survival.
It is conceivable that metastatic tumor cells may have been derived
from a failure of apoptosis or programmed cell death as a result of the
loss of p53 suppressor gene function or activated bcl2 oncogene. The
function of cell-cycle checkpoint mediated by wild-type p53 gene is
to allow sufficient time for the repair of essential genes damaged
by carcinogens. Cells undergo apoptosis after a failure to repair
overwhelming damage to DNA (Kastan et al, 1992); however, recent
work has found no p53 mutations in K-1735 murine metastatic
melanoma cells (Xie et al, 1997), but a C→T transition, a UV signature
mutation, was found in codon 13 of N-ras oncogene in these cells
(Pierceall et al, 1992). As previously discussed (Wei et al, 1997), it is
also conceivable that a highly activated repair mechanism could be
coupled with infidelity of repair in these metastatic cells, which may
explain prevalent genomic instability associated with alterations in
multiple cell-cycle controlling genes observed in metastatic melanoma
cells (Usmani, 1993; Platz et al, 1996).
A recent article shed some light on DNA repair phenotype that
may be conditional on cell growth (Richards et al, 1997). It is very
interesting that cells genetically defective in DNA repair have more
detectable mutations in some essential genes only when the cells are
maintained at high density, a situation relevant to tumor growth in vivo
but less likely to occur in the short-term culture used in the HCR
assay. This may help explain the high mutation rate in p53 observed
in metastatic melanoma cells (Sparrow et al, 1995). Studies that
simultaneously measure DNA repair capacity, alterations in genes
controlling cell cycles, and cell survival of melanoma cells under
different growth conditions should provide clues about their roles in
melanoma tumorigenesis and metastasis.
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